Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Becker's Hospital Review12h
Novo Nordisk expands access to reduced-cost Wegovy
Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Germany’s SAP Overtakes Wegovy Maker Novo Nordisk as Europe’s Most Valuable Company
The business-software group claimed the top spot as Europe’s largest company by market value, dethroning Wegovy maker Novo ...
Fox Business15d
Novo Nordisk shares fall on weight-loss drug trial
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...
Yahoo Finance15d
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...